Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Clin Pharmacol Ther · 2017 · PMC5656880 · PMID 28699160

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

95 A retrospective analysis of 45 RCC patients showed a trend toward increased PFS for patients with a C min ≥14.1 ng/mL of 13.3 vs. 3.9 months, P = 0.06. 96 Based on experience in transplant and pediatric patients, everolimus TDM seems feasible. 94 , 97 Although exposure–response relations are seen for everolimus in oncology, no formal PK‐target has been established yet.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.